My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

Bradley Bolzon Biography and Net Worth

Director of CRISPR Therapeutics

Dr. Bradley Bolzon has served on our Board of Directors since November 2013. He is a Managing Director and Chairman of Versant. Brad combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale), Speedel (sale), Quanticel (sale), Novira (sale), Flexion (2014 IPO), CRISPR (2016 IPO), BioTie (sale), Jecure (sale), Inception (multiple sales) and BlueRock (sale), and he continues to manage several other promising investments. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances at Roche. Under his leadership, Roche established alliances with over 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. Prior to that, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development. He earned Master of Science and Ph.D. degrees in Pharmacology from the University of Toronto.

What is Bradley J. Bolzon's net worth?: The estimated net worth of Bradley J. Bolzon is at least $1.18 million as of June 11th, 2021. Dr. Bolzon owns 24,948 shares of CRISPR Therapeutics stock worth more than $1,179,042 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Bolzon may own. Learn More about Bradley J. Bolzon's net worth.
How do I contact Bradley J. Bolzon?: The corporate mailing address for Dr. Bolzon and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Bradley J. Bolzon's contact information.
Has Bradley J. Bolzon been buying or selling shares of CRISPR Therapeutics?: Bradley J. Bolzon has not been actively trading shares of CRISPR Therapeutics during the past quarter. Most recently, Bradley J. Phd Bolzon sold 10,000 shares of the business's stock in a transaction on Monday, July 19th. The shares were sold at an average price of $126.43, for a transaction totalling $1,264,300.00. Learn More on Bradley J. Bolzon's trading history.
Who are CRISPR Therapeutics' active insiders?: CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?: In the last year, insiders at the sold shares 14 times. They sold a total of 192,740 shares worth more than $12,514,312.47. The most recent insider tranaction occured on November, 11th when CEO Samarth Kulkarni sold 30,000 shares worth more than $1,668,600.00. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.
Information on this page was last updated on 11/11/2024.

Bradley J. Bolzon Insider Trading History at CRISPR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/19/2021	Sell	10,000	$126.43	$1,264,300.00
6/28/2021	Sell	20,375	$152.48	$3,106,780.00	17,159
6/11/2021	Sell	10,000	$126.61	$1,266,100.00	24,948
3/22/2021	Sell	30,374	$132.37	$4,020,606.38	57,149
12/16/2020	Sell	7,648	$148.95	$1,139,169.60	6,734
12/10/2020	Sell	33,000	$143.35	$4,730,550.00	40,648
12/7/2020	Sell	171,004	$154.53	$26,425,248.12	40,648
9/18/2020	Sell	3,035	$86.87	$263,650.45	7,391
9/16/2020	Sell	8,965	$86.98	$779,775.70	7,391
9/14/2020	Sell	1,155	$84.89	$98,047.95	7,391
9/10/2020	Sell	22,845	$85.36	$1,950,049.20	7,391
9/1/2020	Sell	60,000	$92.51	$5,550,600.00
7/6/2020	Sell	20,000	$82.39	$1,647,800.00
6/23/2020	Sell	20,000	$73.93	$1,478,600.00
5/8/2018	Sell	128,950	$50.39	$6,497,790.50	37,645
4/30/2018	Sell	30,566	$50.29	$1,537,164.14	43,986
4/23/2018	Sell	101,994	$50.68	$5,169,055.92	43,986

Bradley J. Bolzon Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $46.22

$45.51

$47.21

50 Day Range

MA: $47.96

$44.90

$54.86

2 Week Range

Now: $46.22

$43.42

$91.10

Volume

709,751 shs

Average Volume

1,481,927 shs

Market Capitalization

$3.94 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

My #1 Pre IPO Trade for 2025 – NAME and TICKER

From Wyatt Investment Research | Ad

The Next SpaceX Pre-IPO